Merck

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

CEO

Robert M. Davis

CEORobert M. Davis

Employees

72,000

Employees72,000

Headquarters

Rahway, New Jersey

HeadquartersRahway, New Jersey

Founded

1891

Founded1891

Employees

72,000

Employees72,000

MRK Key Statistics

Market cap

249.94B

Market cap249.94B

Price-Earnings ratio

20.70

Price-Earnings ratio20.70

Dividend yield

3.16%

Dividend yield3.16%

Average volume

13.05M

Average volume13.05M

High today

$98.56

High today$98.56

Low today

$98.56

Low today$98.56

Open price

$99.10

Open price$99.10

Volume

7.57K

Volume7.57K

52 Week high

$134.63

52 Week high$134.63

52 Week low

$94.48

52 Week low$94.48

MRK News

Seeking Alpha 3d

Merck gets positive EMA opinion for pneumonia vaccine

Merck (NYSE:MRK) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its 21-valent pneumonia...

TipRanks 3d

Merck’s capvaxive receives positive EU CHMP opinion for pneumococcal vaccine

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended the approval of ca...

Simply Wall St 6d

Merck & Co., Inc.'s Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Merck (NYSE:MRK) has had a rough three months with its share price down 5.6%. However, stock prices are usually driven by a company’s financial performance over...

Analyst ratings

67%

of 27 ratings

Buy

66.7%

Hold

33.3%

Sell

More MRK News

Seeking Alpha 7d

Merck gets priority review for Welireg for PPGL

The FDA has accepted Merck's (NYSE:MRK) supplemental New Drug Application with priority review for its drug Welireg, also known as belzutifan, for the treatment...